USANA Health Sciences (NYSE:USNA) had its target price boosted by equities researchers at Pivotal Research from $80.00 to $95.00 in a research note issued on Wednesday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. Pivotal Research’s price target would suggest a potential upside of 28.03% from the company’s current price.

Several other analysts also recently issued reports on the stock. Sidoti downgraded shares of USANA Health Sciences from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 24th. BidaskClub raised shares of USANA Health Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th.

Shares of USANA Health Sciences (NYSE USNA) opened at $74.20 on Wednesday. The company has a market cap of $1,697.47, a P/E ratio of 29.44 and a beta of 0.99. USANA Health Sciences has a 52-week low of $52.55 and a 52-week high of $79.00.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $1.00 by $0.11. The company had revenue of $273.11 million during the quarter, compared to the consensus estimate of $258.67 million. USANA Health Sciences had a net margin of 5.97% and a return on equity of 27.02%. The company’s quarterly revenue was up 8.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.87 EPS.

In related news, major shareholder Global Ltd Gull sold 7,289 shares of USANA Health Sciences stock in a transaction on Monday, November 13th. The shares were sold at an average price of $66.01, for a total value of $481,146.89. Following the completion of the sale, the insider now owns 11,996,192 shares of the company’s stock, valued at approximately $791,868,633.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Myron W. Wentz sold 5,304 shares of USANA Health Sciences stock in a transaction on Monday, November 13th. The shares were sold at an average price of $66.01, for a total transaction of $350,117.04. Following the completion of the sale, the director now directly owns 12,011,418 shares of the company’s stock, valued at approximately $792,873,702.18. The disclosure for this sale can be found here. In the last three months, insiders sold 433,455 shares of company stock valued at $28,990,246. 53.20% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of USNA. Acadian Asset Management LLC boosted its holdings in USANA Health Sciences by 1,867.2% during the 4th quarter. Acadian Asset Management LLC now owns 131,981 shares of the company’s stock worth $9,774,000 after acquiring an additional 125,272 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in USANA Health Sciences by 711.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 91,409 shares of the company’s stock worth $5,859,000 after acquiring an additional 80,145 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in USANA Health Sciences by 148.2% during the 3rd quarter. Wells Fargo & Company MN now owns 67,701 shares of the company’s stock worth $3,907,000 after acquiring an additional 40,420 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in USANA Health Sciences by 5.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 751,018 shares of the company’s stock worth $43,334,000 after acquiring an additional 40,100 shares during the last quarter. Finally, Cornerstone Capital Management Holdings LLC. purchased a new position in USANA Health Sciences during the 3rd quarter worth $1,903,000. 44.26% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/pivotal-research-increases-usana-health-sciences-usna-price-target-to-95-00/1853929.html.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.